



Leiden University
Medical Center

Iki farkli markanin Luminex tek antijen boncuk testlerinin karsilastirilmesi

MFI donusumu icin matematik model



Gonca E. Karahan

TIGED

20-04-2024/ANTALYA



Luminex single antigen bead (SAB) assays are excellent tools to define HLA antibody specificities



Luminex SAB assays: Discrepancies and challenges



- **Test protocol**

Serum/bead ratio, detection antibody, etc.

- **Analysis software**

Positive/negative antibody assignment criteria

- **Various readout types**

Raw MFI, baseline MFI, background corrected MFI (BCM), MFI/LRA, NBG ratio, AD-BCR ...

- Antigen panel composition
- Antigen density
- Antigen integrity


- Background noise in sample
- Interference of serum components (and drugs)

- Lot-to-lot variability
- Day-to-day variability
- Technician variability




Most differences between vendors are observed for low MFI values

HLA class I



Any MFI

MFI>4000



Black: only One Lambda
Gray: only Lifecodes (Immucor)
White: both

Background and aim

- Two vendors (One Lambda=**OL** and Lifecodes/Immucor=**LC**) provide Luminex SAB tests and many centers use both tests simultaneously or switch from one to another
- Due to differences in manufacturing process and design, MFI values between vendors are not comparable
- Cut-offs based on the same (numeric) MFI values cannot be applied for both vendors

AIMS:

- Generate a model to determine how MFI values from different vendors behave with respect to each other
- Establish data-driven, comparable, vendor-specific cutoffs for analyzing big data sets


Study cohort – negative control beads

Exploration dataset (n=24)
(Pregnancy-immunized women)


Validation dataset (n=12)
(Pregnancy-immunized women)

Transplantation set (n=11)
(Kidney tx patients, post-tx serum)


Exploration dataset



Validation dataset




Transplantation dataset



Some samples had high negative control bead MFI values but were not excluded from the study.

Samples

- All serum samples were **EDTA-treated**
- **OL test:** 20 µl serum/4 µl beads
- **LC test:** 7.5 µl serum/30 µl beads¹
- Luminex SAB tests were performed over a **3-year period** (2019-2021)
- **Various lots** of single antigen beads were used by **different technicians**
- A LabScan 100 device was used for data acquisition
- Only **common beads** were analyzed
- Every common bead had at least **one positive MFI value in the study cohort** (exploration/validation)



¹Kamburova et al. HLA, 2016

Study design-workflow

Step 1: No decision is made

Generation and validation of a model to “convert” MFI values of one vendor to other and vice versa

Interpolation of the MFI values when the highest correlation (r^2) is achieved in all cases
Better correlation, better prediction (perfect correlation is impossible!)


Step 2: Decisions are made

Decision for positive and negative beads with cutoffs based on interpolated values


Non-linear hyperbola model fits the data better than the linear model

Exploration set
n=24

Class I




Class I



Correction for self HLA improves the goodness of the fit of the model


Exploration set
n=24

Correction self-HLA: Locus-specific highest self HLA MFI was subtracted from raw MFI of specific bead



Exclude samples with background : $R^2 = 0.943$

Interpolations from one vendor to the other



Locus-specific interpolations

HLA locus	Correction	Model	Exploration Cohort			
			N	R ²	Interpolated MFI OL	
					LC=1000	LC=3000
HLA Class I	Raw MFI & Self-HLA	Hyperbola	2016	0,946	5044	10830
HLA-A	Raw MFI & Self-HLA	Hyperbola	672	0,933	4942	10768
HLA-B	Raw MFI & Self-HLA	Hyperbola	1032	0,953	5010	10759
HLA-C	Raw MFI & Self-HLA	Hyperbola	312	0,889	6647	12505

✓ **Similar trends** were observed for interpolations in **both exploration and validation** datasets

Workflow-Step 2

- What happens if we use these interpolated values as cutoff values to assign a bead positive/negative?
 - How good is the quality of these assignments? (statistically)
 - Are there any (interesting) outliers?

Model: Hyperbola, self-HLA corrected raw MFI, locus-specific

Quality of assignments: Lifecodes → One Lambda

Exploration Cohort											
MFI LC	MFI OL	locus	LC/OL neg/neg	LC/OL pos/neg	LC/OL neg/pos	LC/OL pos/pos	specificity (%)	sensitivity (%)	accuracy (%)	r_φ	N
1000	4942	HLA-A	408	16	13	235	96.2	94.8	95.7	0.908	672

Specificity: True negatives

Sensitivity: True positives

Accuracy: Proportion of true results

Quality of assignments: One Lambda → Lifecodes

	Exploration Cohort										
MFI OL	MFI LC	locus	LC/OL neg/neg	LC/OL pos/neg	LC/OL neg/pos	LC/OL pos/pos	specificity	sensitivity	accuracy	r_ϕ	N
3000	556	HLA-A	384	6	8	274	98,5%	97,2%	97,9%	0.957	672
8000	1890	HLA-A	465	26	26	155	94,7%	85,6%	92,3%	0.803	672
3000	545	HLA-B	539	12	20	461	97,8%	95,8%	96,9%	0.937	1032
8000	1874	HLA-B	680	19	19	314	97,3%	94,3%	96,3%	0.915	1032
3000	336	HLA-C	269	3	11	29	98,9%	72,5%	95,5%	0.786	312
8000	1317	HLA-C	295	3	2	12	99,0%	85,7%	98,4%	0.819	312
3000	1435	HLA-DR	560	13	19	176	97,7%	90,3%	95,8%	0.889	768
8000	4447	HLA-DR	637	14	5	112	97,8%	95,7%	97,5%	0.908	768
3000	531	HLA-DQ	301	11	8	88	96,5%	91,7%	95,3%	0.872	408
8000	1869	HLA-DQ	331	10	5	62	97,1%	92,5%	96,3%	0.870	408
3000	1517	HLA-DP	286	1	0	49	99,7%	100,0%	99,7%	0.988	336
8000	4346	HLA-DP	317	3	0	16	99,1%	100,0%	99,1%	0.913	336


Outliers: Beads outside 95% prediction intervals

Approach: For a given MFI value in one vendor, we compared the observed MFI with the expected (predicted) MFI for the other vendor.

cohort	bead	observed LC	observed OL	expected OL
exploration	A*80:01 17V	8260	21671	17236
validation	A*80:01 19A	958	12334	5796
validation	A*80:01 17C	913	11606	5580

Criteria:

- Always in one direction in both cohorts
- Occurring ≥ 2 times in both cohorts



Agreement of two vendors for outliers


Bead	Values outside prediction intervals			
	exploration set		validation set	
	lower	higher	lower	higher
B*47:01	0	8	0	4
B*48:01	7	0	4	0
B*42:01	3	0	2	0
B*46:01	2	0	2	0
C*05:01	3	0	3	0
DQB1*05:01-DQA1*01:01	5	0	2	0
DQB1*06:01-DQA1*01:03	4	0	2	0
DRB1*01:01	2	0	2	0

Cut-off MFI LifeCodes = 1000, OneLambda MFI = interpolated			
exploration set		validation set	
LC/OL neg/pos	LC/OL pos/neg	LC/OL neg/pos	LC/OL pos/neg
0	2	0	1
2	0	1	0
1	0	1	0
0	0	1	0
0	0	0	0
1	0	1	0
0	0	1	0
0	0	0	0



Cut-off OneLambda = 3000, MFI Lifecodes = interpolated			
exploration set		validation set	
LC/OL neg/pos	LC/OL pos/neg	LC/OL neg/pos	LC/OL pos/neg
0	1	0	1
0	0	1	0
1	0	1	0
1	0	1	0
2	0	2	0
1	0	0	0
0	0	1	0
0	0	0	0

Not all outliers resulted in disagreement!



Consistency of the model was verified in an independent validation dataset



Consistency of the model was verified in an independent validation dataset



Consistency of the model was verified in a transplantation dataset



Disagreements in bead-specific reactivity assignments in transplantation dataset

- Post-tx serum from kidney transplant recipients (n=11)
- Bead-specific reactivity for a total of 87 HLA mismatches (HLA-A, -B, -C, -DR, -DQ, -DP) was assessed
- Overall agreement: 94 %

Cutoff: Lifecodes (1000 MFI) and interpolated OL MFI		MFI observed	
Patient #	Bead	LC	OL
7	A*01:01	1121	223
4	C*01:02	1260	6122
3	DRB1*07:01	1028	2328
9	DRB3*01:01	3529	32
7	DQB1*02:01-DQA1*05:01	293	13775

Cut-off	
LC	int OL (tx)
1000	3479
1000	6403
1000	3073
1000	3073
1000	4083

Bead-specific reactivity	
LC	OL (tx)
pos	neg
pos	neg
pos	neg
pos	neg
neg	pos

Cutoff: One Lambda (3000 MFI) and interpolated LC MFI		MFI observed	
Patient #	Bead	OL	LC
7	A*01:01	223	1121
<u>11</u>	C*03:04	2952	892
3	DRB1*07:01	2328	1028
9	DRB3*01:01	32	3529
7	DQB1*02:01-DQA1*05:01	13775	293
<u>7</u>	DQB1*05:02-DQA1*01:02	32	807

Cut-off	
OL	int LC (tx)
3000	621
3000	331
3000	738
3000	738
3000	662
3000	662

Bead-specific reactivity	
OL	LC (tx)
neg	pos
neg	pos
neg	pos
neg	pos
pos	neg
neg	pos

Concluding remarks

- ✓ The current model (non-linear hyperbola with self HLA correction) will help to establish comparable MFI cutoffs for the two different kits, **at least on the population level (big data analyses)**
- ✓ For **individual patients**, variation in the two assays per specificity **precludes MFI conversion** from one vendor to the other



Leiden University
Medical Center

Acknowledgements

Geert Haasnoot

Kim Voogt-Bakker

Frans Claas

Dave Roelen

Sebastiaan Heidt



National Reference Center for Histocompatibility Testing, Leiden, the Netherlands